FDA draft guidance aims to speed personalized gene therapies for rare diseases
Read original article on Breaking News on Seeking Alpha →Related news
-
Federal Realty signals $7.54-$7.58 core FFO per share guidance while integrating $508M The Summit acquisition
Business
Real Estate
United States
- Exxon plans to spend $10B on refining business to boost margins, CEO says Business Corporate United States
- Chevron outlines plan to double Venezuela joint venture output to ~600,000 bpd by 2031 Business Corporate Venezuela
- Piper Sandler signals $200M buyback through 2028 as it expects strongest quarter of 2026 in Q4 Business Corporate
- Mohawk anticipates Q4 adjusted EPS of $1.35-$1.45 while launching new $500M buyback Business Corporate United States
- Imperial Oil targets 280,000 bpd gross annual production at Kearl while positioning for added shareholder cash returns in 2027 Business Corporate Canada
-
GFL investor relations exit unrelated to potential deal - CTFN
Business
Corporate
-
New Break Resources plans C$550K financing to fund Moray gold drilling
Business